MARKET

CMRX

CMRX

Chimerix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.620
-0.010
-0.38%
Closed 16:00 09/25 EDT
OPEN
2.600
PREV CLOSE
2.630
HIGH
2.673
LOW
2.550
VOLUME
308.69K
TURNOVER
--
52 WEEK HIGH
3.885
52 WEEK LOW
1.190
MARKET CAP
162.93M
P/E (TTM)
-1.5893
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
What Kind Of Shareholders Own Chimerix, Inc. (NASDAQ:CMRX)?
Simply Wall St. · 09/13 15:21
Chimerix to Participate in Upcoming Investor Conferences
DURHAM, N.C., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that management will participate in the following investor conferences in September:
GlobeNewswire · 09/10 13:00
Chimerix EPS beats by $0.01, misses on revenue
Chimerix (NASDAQ:CMRX): Q2 GAAP EPS of -$0.16 beats by $0.01. Revenue of $1.4M (-2.8% Y/Y) misses by $0.19M. Press Release
seekingalpha · 08/10 16:02
Chimerix (CMRX) Reports Q2 Loss, Tops Revenue Estimates
Chimerix (CMRX) delivered earnings and revenue surprises of 11.11% and 19.83%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/10 12:25
Recap: Chimerix Q2 Earnings
Shares of Chimerix (NASDAQ:CMRX) were flat in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share rose 54.29% year over year to ($0.16), which beat the estimate of ($0.17).Revenue of $1,402,000 declined by 2.50% from t
Benzinga · 08/10 11:28
Chimerix Q2 EPS $(0.16) Beats $(0.17) Estimate, Sales $1.40M Beat $1.06M Estimate
Chimerix (NASDAQ:CMRX) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.17) by 5.88 percent. This is a 54.29 percent increase over losses of $(0.35) per share from the same
Benzinga · 08/10 11:07
Chimerix Reports Second Quarter 2020 Financial Results and Provides Operational Update
– Completion of BCV NDA Rolling Submission Planned for Third Quarter 2020 – –  Currently Enrolling Phase 2/3 Study of DSTAT in Patients with COVID-19;  Phase 2 Enrollment Completion Expected in Fourth Quarter –– Startup Activities for DSTAT Phase 3 AML Study
GlobeNewswire · 08/10 11:00
Chimerix to Report Second Quarter 2020 Financial Results and Provide an Operational Update on August 10, 2020
DURHAM, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and au
GlobeNewswire · 08/03 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CMRX. Analyze the recent business situations of Chimerix through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CMRX stock price target is 6.67 with a high estimate of 10.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 126
Institutional Holdings: 39.23M
% Owned: 63.08%
Shares Outstanding: 62.19M
TypeInstitutionsShares
Increased
26
1.27M
New
27
2.00M
Decreased
27
4.58M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Independent Director
Martha Demski
President/Chief Executive Officer/Director
Michelle Berrey
President/Chief Executive Officer/Director
Michael Sherman
Chief Financial Officer
Michael Andriole
Chief Executive Officer
W. Garrett Nichols
Senior Vice President/General Counsel
Michael Alrutz
Independent Director
Catherine Gilliss
Chief Accounting Officer
David Jakeman
Independent Director
Edward Greissing
Independent Director
Patrick Machado
Independent Director
Robert Meyer
Independent Director
Fred Middleton
Independent Director
C. Patrick Machado
Independent Director
Pratik Multani
Independent Director
Clarence Machado
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CMRX
Chimerix, Inc. is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses. It is also advancing the development of CMX521 for the treatment and prevention of norovirus. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against all five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. Oral and IV formulations of brincidofovir are in development, both of which deliver the active antiviral directly to the site of viral replication.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Chimerix Inc stock information, including NASDAQ:CMRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CMRX stock methods without spending real money on the virtual paper trading platform.